Pàgina inicial > Articles > Resultats de la cerca: Biomarker

Articles

  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Articles 134 registres trobats  anterior11 - 20següentfinal  anar al registre: La cerca s'ha fet en 0.03 segons. 
11.
10 p, 1.8 MB A proposed approach to chronic airway disease (CAD) using therapeutic goals and treatable traits : A look to the future / Pérez de Llano, Luis (University Hospital Lucus Augusti (Lugo, Galícia)) ; Miravitlles, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Golpe, Rafael (University Hospital Lucus Augusti (Lugo, Galícia)) ; Alvarez Gutiérrez, Francisco Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Cisneros, Carolina (Hospital Universitario La Princesa (Madrid)) ; Almonacid, Carlos (Hospital Universitario Ramón y Cajal (Madrid)) ; Martínez-Moragón, Eva (Hospital Universitari Doctor Peset (València)) ; González-Barcala, Francisco-Javier (Universidade de Santiago de Compostela) ; Ramos-Barbón, David (Institut d'Investigació Biomèdica Sant Pau) ; Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau) ; López-Campos, José Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; De Torres, Juan Pablo (Queen's University) ; Casanova Macario, Ciro (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ; García-Rivero, J. L. (Hospital de Laredo) ; Rodriguez Hermosa, Juan Luis (Hospital Clínico San Carlos (Madrid)) ; Calle Rubio, Myriam (Hospital Clínico San Carlos (Madrid)) ; Soler-Cataluña, Juan José (Hospital Arnau de Vilanova (València)) ; Cosio, Borja G (Clínica Quirón-Rotger) ; Universitat Autònoma de Barcelona
Chronic airflow obstruction affects a wide range of airway diseases, the most frequent of which are asthma, COPD, and bronchiectasis; they are clearly identifiable in their extremes, but quite frequently overlap in some of their pathophysiological and clinical characteristics. [...]
2020 - 10.2147/COPD.S263430
International journal of COPD, Vol. 15 (2020) , p. 2091-2100  
Registre complet - Creative Commons
12.
15 p, 1.9 MB In silico Approach for Validating and Unveiling New Applications for Prognostic Biomarkers of Endometrial Cancer / Coll de la Rubia, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Martinez-Garcia, Elena (Luxembourg Institute of Health) ; Dittmar, Gunnar (Luxembourg Institute of Health) ; Nazarov, Petr V. (Luxembourg Institute of Health) ; Bebia, Vicente (Hospital Universitari Vall d'Hebron) ; Cabrera Díaz, Silvia (Hospital Universitari Vall d'Hebron) ; Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron) ; Colás Ortega, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Endometrial cancer (EC) mortality is directly associated with the presence of poor prognostic factors. Molecular prognostic factors have been identified, but none are used in clinical practice due to lack of validation studies. [...]
2021 - 10.3390/cancers13205052
Cancers, Vol. 13 (october 2021)  
Registre complet - Creative Commons
13.
11 p, 1.6 MB Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke / Garcia-Rodriguez, Nicolás (Hospital Universitari Vall d'Hebron) ; Rodriguez, Susana (Hospital Universitari Vall d'Hebron) ; Tejada, Pedro Ignacio (Unidad de Daño Cerebral del Hospital de Górliz) ; Miranda-Artieda, Zuberoa Maite (Unidad de Daño Cerebral del Hospital de Górliz) ; Ridao, Natalia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Buxo Masip, Xavier (Hospital Universitari Vall d'Hebron) ; Pérez-Mesquida, María Engracia (Hospital Universitari Vall d'Hebron) ; Beseler, Maria Rosario (Hospital Universitari i Politècnic La Fe (València)) ; Salom, Juan B. (Universitat de València) ; Pérez, Laura M. (Hospital Universitari Vall d'Hebron) ; Inzitari, Marco (Hospital Universitari Vall d'Hebron) ; Otero-Villaverde, Sergio (Hospital Marítimo de Oza) ; Martin-Mourelle, Rosa (Hospital Marítimo de Oza) ; Molleda, Mercedes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Quintana, Manuel (Hospital Universitari Vall d'Hebron) ; Olivé-Gadea, Marta (Hospital Universitari Vall d'Hebron) ; Penalba, Anna (Hospital Universitari Vall d'Hebron) ; Rosell Novel, Anna (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. [...]
2021 - 10.3389/fneur.2021.767484
Frontiers in neurology, Vol. 12 (november 2021)  
Registre complet - Creative Commons
14.
19 p, 7.5 MB Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab / Granell-Geli, Júlia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Izquierdo-Gracia, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sellés-Rius, Ares (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mansilla Lopez, Maria Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Brieva Ruiz, Luis (Hospital Universitari Arnau de Vilanova) ; Sotoca Fernández, Javier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Mañé-Martínez, María Alba (Hospital Universitari Joan XXIII de Tarragona) ; Moral, Ester (Hospital de Sant Joan Despí Moisès Broggi) ; Bragado, Irene (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Goelz, Susan (Biogen Idec) ; Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. [...]
2021 - 10.3390/jpm11121347
Journal of personalized medicine, Vol. 11 (december 2021)  
Registre complet - Creative Commons
15.
14 p, 1002.6 KB Circulating MicroRNAs as a Tool for Diagnosis of Liver Disease Progression in People Living with HIV-1 / Martinez, Miguel Angel (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Tural, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Franco Cirera, Sandra (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Universitat Autònoma de Barcelona
MicroRNAs (miRNAs) are small, non-coding RNAs that post-transcriptionally regulate gene expression by binding specific cell mRNA targets, preventing their translation. miRNAs are implicated in the regulation of important physiological and pathological pathways. [...]
2022 - 10.3390/v14061118
Viruses, Vol. 14 (may 2022)  
Registre complet - Creative Commons
16.
4 p, 880.7 KB β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer's disease / Mohaupt, Pablo (Université de Montpellier) ; Pons, Marie-Laure (Université de Montpellier) ; Vialaret, Jérôme (Université de Montpellier) ; Delaby, Constance (Institut d'Investigació Biomèdica Sant Pau) ; Hirtz, Christophe (Université de Montpellier) ; Lehmann, Sylvain (Université de Montpellier) ; Universitat Autònoma de Barcelona
Synaptic degeneration is an early event closely associated with the course of Alzheimer's disease (AD). The identification of synaptic blood biomarkers is, therefore, of great interest and clinical relevance. [...]
2022 - 10.1186/s13195-022-01125-1
Alzheimer's research & therapy, Vol. 14 (november 2022)  
Registre complet - Creative Commons
17.
19 p, 3.1 MB Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients / Lennol, Matthew Paul (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ; Sánchez-Domínguez, Irene (Universitat de Barcelona. Institut de Neurociències) ; Cuchillo-Ibañez, Inmaculada (Instituto de Investigación Sanitaria y Biomédica de Alicante) ; Camporesi, Elena (Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry. the Sahlgrenska Academy at the University of Gothenburg) ; Brinkmalm, Gunnar (Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry. the Sahlgrenska Academy at the University of Gothenburg) ; Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Soria, Guadalupe (Universitat de Barcelona. Laboratori de Neuroanatomia Quirúrgica. Facultat de Medicina i Ciències de la Salut) ; Aguado, Fernando (Universitat de Barcelona. Institut de Neurociències) ; Zetterberg, Henrik (Hong Kong Center for Neurodegenerative Diseases) ; Blennow, Kaj (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital) ; Sáez-Valero, Javier (Instituto de Investigación Sanitaria y Biomédica de Alicante) ; Universitat Autònoma de Barcelona
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. [...]
2022 - 10.1186/s13195-022-01108-2
Alzheimer's research & therapy, Vol. 14 Núm. 1 (december 2022) , p. 161  
Registre complet - Creative Commons
18.
19 p, 1.3 MB State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease / Hampel, Harald (Eisai Inc. Neurology Business Group) ; Shaw, Leslie M. (Perelman School of Medicine. Department of Pathology and Laboratory Medicine. University of Pennsylvania) ; Aisen, Paul (USC Alzheimer's Therapeutic Research Institute) ; Chen, Christopher (Memory Aging and Cognition Centre. Departments of Pharmacology and Psychological Medicine. Yong Loo Lin School of Medicine. National University of Singapore) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Iwatsubo, Takeshi (Department of Neuropathology. Graduate School of Medicine. The University of Tokyo) ; Iwata, Atsushi (Tokyo Metropolitan Geriatric Hospital) ; Yamada, Masahito (Department of Neurology and Neurobiology of Aging. Kanazawa University Graduate School of Medical Science) ; Ikeuchi, Takeshi (Department of Molecular Genetics. Brain Research Institute. Niigata University) ; Jia, Jianping (Innovation Center for Neurological Disorders. Department of Neurology. Xuan Wu Hospital. Capital Medical University) ; Wang, Huali (Dementia Care and Research Center. Peking University Institute of Mental Health (Sixth Hospital). Beijing Dementia Key Lab. National Clinical Research Center for Mental Disorders) ; Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ; Peskind, Elaine (VA Northwest Mental Illness Research. Education and Clinical Center. VA Puget Sound Health Care System. Department of Psychiatry and Behavioral Sciences. University of Washington School of Medicine) ; Blennow, Kaj (Clinical Neurochemistry Laboratory. Sahlgrenska University Hospital) ; Cummings, Jeffrey (Chambers-Grundy Center for Transformative Neuroscience. Department of Brain Health. School of Integrated Health Sciences. University of Nevada Las Vegas (UNLV)) ; Vergallo, Andrea (Eisai Inc. Neurology Business Group) ; Universitat Autònoma de Barcelona
Recent advances in developing disease-modifying therapies (DMT) for Alzheimer's disease (AD), and the recognition that AD pathophysiology emerges decades before clinical symptoms, necessitate a paradigm shift of health-care systems toward biomarker-guided early detection, diagnosis, and therapeutic decision-making. [...]
2022 - 10.1002/alz.12372
Alzheimer's & Dementia, Vol. 18 Núm. 1 (january 2022) , p. 159-177  
Registre complet - Creative Commons
19.
13 p, 1.7 MB A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management / Bradbury, Melissa (Hospital Universitari Vall d'Hebron) ; Borràs, Eva (Universitat Pompeu Fabra) ; Vilar, Marta (Hospital Universitari Vall d'Hebron) ; Castellvi, Josep (Hospital Universitari Vall d'Hebron) ; Sanchez Iglesias, Jose Luis (Hospital Universitari Vall d'Hebron) ; Pérez-Benavente, Assumpció (Hospital Universitari Vall d'Hebron) ; Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron) ; Fàbrega-Santamaria, Anna (Hospital Universitari Vall d'Hebron) ; Sabidó, Eduard (Universitat Pompeu Fabra) ; Universitat Autònoma de Barcelona
High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-based chemotherapy, up to a quarter will be resistant to treatment. [...]
2022 - 10.1186/s12967-022-03816-7
Journal of translational medicine, Vol. 20 (december 2022)  
Registre complet - Creative Commons
20.
19 p, 365.1 KB Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis : Recent Developments and Therapeutic Applications / Sánchez-Tejerina, Daniel (Hospital Universitari Vall d'Hebron) ; Llaurado, Arnau (Hospital Universitari Vall d'Hebron) ; Sotoca Fernández, Javier (Hospital Universitari Vall d'Hebron) ; Lopez-Diego, Veronica (Hospital Universitari Vall d'Hebron) ; Vidal Taboada, Jose M. (Hospital Universitari Vall d'Hebron) ; Salvado, Maria (Hospital Universitari Vall d'Hebron) ; Juntas Morales, Raúl (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by the degeneration of motor neurons for which effective therapies are lacking. One of the most explored areas of research in ALS is the discovery and validation of biomarkers that can be applied to clinical practice and incorporated into the development of innovative therapies. [...]
2023 - 10.3390/cells12081180
Cells, Vol. 12 (april 2023)  
Registre complet - Creative Commons

Articles : 134 registres trobats   anterior11 - 20següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem